As previously disclosed, WntResearch has submitted patent applications for two different synthetic pathways to reduce manufacturing costs and streamline the commercial-scale Foxy-5 manufacturing. The patents filed will further protect important building blocks required for the efficient production of Foxy-5. The positive opinion provides WntResearch with a considerable and enhanced protection for manufacturing of Foxy-5 beyond 2035.
The currently employed Foxy-5 manufacturing process is costly, and it is considered that it would pose severe challenges in the future when production would need to take place on a larger scale. The novel process, which the patents will protect, represents a scalable manufacturing process as well as a significant reduction of manufacturing cost.
"A crucial aspect of the future Foxy-5 commercialization is to keep the manufacturing cost under control and to ensure a high degree of quality at the production level. The new manufacturing process allows us to improve the cost efficiency and the quality of production at the same time, and safeguard Foxy-5 globally," says Peter Morsing, CEO of WntResearch.
For more information, please contact:
Peter Morsing, CEO, WntResearch AB
Telephone: +46 727 200711
This information is information that WntResearch AB is obliged to make public
pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency
of the contact person set out above, on Friday, 10 July 2020.
WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The Company focuses on WNT5A, a protein that suppresses the metastatic process in the body; the vision is for cancer patients to no longer have to endure metastasis. Today, one in every three people will develop cancer during their lifetimes, and 90 percent of all cancer-related deaths are caused by metastases. Even though cancer treatment has become more effective, there are no effective methods to prevent the formation of metastasis. The drug candidate Foxy-5 mimics WNT5A’ s ability to reduce the mobility and thus the spread of cancer cells. Foxy-5 has demonstrated a good safety profile with few adverse effects in two clinical phase I studies. An ongoing clinical phase II study is currently being conducted on patients with colon cancer with the Company's drug candidate Foxy-5. According to the Company's assessment, Foxy-5 is the only drug candidate of its kind, with a unique mode of action in an area where other drug or treatment options are lacking. WntResearch’s share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com